StockIQpro
NASDAQ:ARTL

Artelo Biosciences, Inc.

Track all markets on TradingView
Track all markets on TradingView

Artelo Biosciences, Inc. reported net income of −$12.9M in fiscal 2025. The diluted share count rose 91.6%.Summary generated from Artelo Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−1625.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+91.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−9−10−10−10−11
Net income−9−10−9−10−13
Free cash flown/an/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations